In light of these cross-sectional data supporting the specificity and sensitivity of APP levels as indices of disease burden, disease progression, and survival in ALS, the next question is whether longitudinal APP data accurately monitor disease burden and progression. This evidence concerns the gene APP and amyotrophic lateral sclerosis.